On May 8-9, 1998 NACB is sponsoring a Standards of Laboratory Practice Meeting on Guidelines on the Use of Tumor Markers for the Diagnosis and Monitoring of Cancer. This 1.5 day SOLP is being held as a joint meeting with the Clinical Ligand Assay Society as part of its Annual Meeting, May 6-9 at the Rye Town Hilton Hotel, Rye Brook, New York. The purpose of the SOLP is to develop and publish guidelines or recommendations for the use of laboratory tests for the monitoring and diagnosis of cancer. The draft recommendations will appear below when available.

For registration or other information, contact:
Joint CLAS / NACB Meeting, c/o CLAS,
3139 S. Wayne Road, Wayne, MI 48184;
phone 313-722-6290;
fax 313-722-7006;
email: clas@rust.net;
home page: http://www.clas.org

Tentative Program
Scientific Chair: Martin Fleisher, Ph.D.

Friday, May 8 - Morning

Session I: Guidelines for the Use of Tumor Markers for the Detection of Primary and Metastatic Cancer

James L. Wittliff, PhD
Breast Cancer - Early Stage, Late Stage

Nancy Kemeny, MD
Colorectal and Pancreatic Cancer - Early Stage, Late Stage

Daniel W. Chan, PhD & Allan Partin, MD, PhD
Prostate Cancer - Monitoring Disease - Early Stage

Martin Fleisher, PhD
Neuroendocrine Tumors

Robert Kyle, MD & Tom Habermann, MD
Myeloma and Lymphoma

Friday, May 8 - Afternoon

Robert Bast, MD
Ovarian and Uterine Cancer

George Bosi, MD & Dean Bajorin, MD
Germ Cell and Trophoblastic Tumors

Saturday, May 9

Session II: Tumor Marker Assay Standardization, Predictive Indicators, and Panel Tests

Herbert Fritsche, PhD
Tumor Marker Assay Standardization and Assay Concordance

Morton K. Schwartz, PhD
Tumor Marker "Battery Testing" - Is It Helpful?

Eletherios Diamandis, MD, PhD & Gary Clark, PhD
Prognostic and Predictive Markers for Cancer

Stanley Hamilton, PhD
Detecting Cancer in the 21st Century